Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
- 51 Downloads
Andexanet alfa (Andexxa®), a first-in-class recombinant modified factor Xa protein, is currently the only specific agent available to reverse life-threatening or uncontrolled bleeding with the factor Xa inhibitors apixaban and rivaroxaban. Andexanet alfa acts as a decoy and competes with endogenous factor Xa to bind factor Xa inhibitors, thereby reversing the anticoagulant effects of factor Xa inhibitors, and restoring the activity of endogenous factor Xa. In adults with major bleeding associated with the use of apixaban or rivaroxaban, intravenous administration of andexanet alfa effectively and rapidly reduces anti-factor Xa levels, with reduced levels being maintained during continued treatment. The tolerability profile of andexanet alfa in patients is generally similar to that reported of other approved anticoagulation reversal agents. With the known increased risk of thromboembolic events following andexanet alfa treatment, anticoagulant therapy should be resumed as soon as medically appropriate.
The manuscript was updated from Drugs 2018;78(10):1049–55 , and was reviewed by: J. E. Ansell, Hofstra Northwell School of Medicine, Hempstead, NY, USA; N. Ali, Department of Pathology and Laboratory Medicine/Oncology, The Aga Khan University Hospital, Karachi, Pakistan; J. D. Douketis, Department of Medicine, McMaster University, Hamilton, ON, Canada. During the peer review process, Portola Pharmaceuticals, Inc., the marketing-authorization holder of andexanet alfa, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received will be made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Y.-A. Heo is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
- 5.Dabi A, Koutrouvelis AP. Reversal strategies for intracranial hemorrhage related to direct oral anticoagulant medications. Crit Care Res Pract. 2018;2018(4907164):1–11.Google Scholar
- 8.Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) lyophilized powder for solution for intravenous injection: US prescribing information. South San Franciso: Portola Pharmaceuticals, Inc.; 2018.Google Scholar
- 12.Grottke O, Akman N, Conley PB, et al. The impact of andexanet alfa in a porcine polytrauma model under apixaban anticoagulation: investigation of hemostatic safety and efficacy [abstract no. 20205]. Circulation. 2017;136(Suppl 1).Google Scholar
- 14.Mark C, Vandana M, Michael K, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXA inhibitors [abstract]. Blood. 2013;122(21):3.Google Scholar
- 16.Lu G, Lin J, Curnutte JT, et al. Effect of andexanet-tissue factor pathway inhibitor (TFPI) interaction on in vitro clot formation and lysis via different coagulation pathways [slide presentation]. In: International Society on Thrombosis and Haemostasis. 2018.Google Scholar
- 18.Connolly S, Milling T, Eikelboom JW, et al. Andexanet alfa in factor Xa inhibitor-associated acute major bleeding [abstract plus slide presentation]. In: American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC18); 2018.Google Scholar